Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome.

Araki T, Dahlberg SE, Hida T, Lydon CA, Rabin MS, Hatabu H, Johnson BE, Nishino M.

Eur J Radiol Open. 2019 Mar 29;6:128-131. doi: 10.1016/j.ejro.2019.03.003. eCollection 2019.

2.

M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome.

Park H, Dahlberg SE, Lydon CA, Araki T, Hatabu H, Rabin MS, Johnson BE, Nishino M.

Oncologist. 2019 Aug;24(8):e749-e754. doi: 10.1634/theoncologist.2018-0596. Epub 2019 Jan 29.

PMID:
30696724
3.

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.

Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA.

JAMA Oncol. 2018 Nov 1;4(11):1527-1534. doi: 10.1001/jamaoncol.2018.2969.

4.

Algorithm-based decision support for symptom self-management among adults with Cancer: results of usability testing.

Cooley ME, Abrahm JL, Berry DL, Rabin MS, Braun IM, Paladino J, Nayak MM, Lobach DF.

BMC Med Inform Decis Mak. 2018 May 29;18(1):31. doi: 10.1186/s12911-018-0608-8.

5.

Clinician perspectives on symptom and quality of life experiences of patients during cancer therapies: Implications for eHealth.

Berry DL, Nayak MM, Abrahm JL, Braun I, Rabin MS, Cooley ME.

Psychooncology. 2017 Aug;26(8):1113-1119. doi: 10.1002/pon.4455. Epub 2017 Jul 3.

PMID:
28497471
6.

Patient and caregiver perspectives on decision support for symptom and quality of life management during cancer treatment: Implications for eHealth.

Cooley ME, Nayak MM, Abrahm JL, Braun IM, Rabin MS, Brzozowski J, Lathan C, Berry DL.

Psychooncology. 2017 Aug;26(8):1105-1112. doi: 10.1002/pon.4442. Epub 2017 Jul 3.

PMID:
28430396
7.

Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung Cancer.

Jackman DM, Zhang Y, Dalby C, Nguyen T, Nagle J, Lydon CA, Rabin MS, McNiff KK, Fraile B, Jacobson JO.

J Oncol Pract. 2017 Apr;13(4):e346-e352. doi: 10.1200/JOP.2017.021741. Epub 2017 Mar 4.

PMID:
28260402
8.

Case report of tracheobronchial squamous cell carcinoma treated with radiation therapy and concurrent chemotherapy.

Agrawal V, Marcoux JP, Rabin MS, Vernovsky I, Wee JO, Mak RH.

Adv Radiat Oncol. 2016 Apr 1;1(2):127-131. doi: 10.1016/j.adro.2016.03.003. eCollection 2016 Apr-Jun. No abstract available.

9.

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.

Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cibulskis K, Ligon KL, Tabernero J, Seoane J, Martinez-Saez E, Curry WT, Dunn IF, Paek SH, Park SH, McKenna A, Chevalier A, Rosenberg M, Barker FG 2nd, Gill CM, Van Hummelen P, Thorner AR, Johnson BE, Hoang MP, Choueiri TK, Signoretti S, Sougnez C, Rabin MS, Lin NU, Winer EP, Stemmer-Rachamimov A, Meyerson M, Garraway L, Gabriel S, Lander ES, Beroukhim R, Batchelor TT, Baselga J, Louis DN, Getz G, Hahn WC.

Cancer Discov. 2015 Nov;5(11):1164-1177. doi: 10.1158/2159-8290.CD-15-0369. Epub 2015 Sep 26.

10.

A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer.

Jackman DM, Cioffredi LA, Jacobs L, Sharmeen F, Morse LK, Lucca J, Plotkin SR, Marcoux PJ, Rabin MS, Lynch TJ, Johnson BE, Kesari S.

Oncotarget. 2015 Feb 28;6(6):4527-36.

11.

Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival.

Nishino M, Cardarella S, Dahlberg SE, Araki T, Lydon C, Jackman DM, Rabin MS, Hatabu H, Johnson BE.

Eur J Radiol. 2015 May;84(5):998-1004. doi: 10.1016/j.ejrad.2015.01.021. Epub 2015 Feb 7.

12.

Recurrent radiation necrosis in the brain following stereotactic radiosurgery.

Parker GM, Dunn IF, Ramkissoon SH, Eneman JD, Rabin MS, Arvold ND.

Pract Radiat Oncol. 2015 May-Jun;5(3):e151-4. No abstract available.

PMID:
25432541
13.

Feasibility of using algorithm-based clinical decision support for symptom assessment and management in lung cancer.

Cooley ME, Blonquist TM, Catalano PJ, Lobach DF, Halpenny B, McCorkle R, Johns EB, Braun IM, Rabin MS, Mataoui FZ, Finn K, Berry DL, Abrahm JL.

J Pain Symptom Manage. 2015 Jan;49(1):13-26. doi: 10.1016/j.jpainsymman.2014.05.003. Epub 2014 May 29.

14.

Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression.

Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Ramaiya NH, Hatabu H, Jänne PA, Johnson BE.

Cancer. 2013 Nov 1;119(21):3761-8. doi: 10.1002/cncr.28290. Epub 2013 Aug 6.

15.

RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.

Nishino M, Cardarella S, Jackman DM, Ramaiya NH, Rabin MS, Hatabu H, Jänne PA, Johnson BE.

AJR Am J Roentgenol. 2013 Jul;201(1):W64-71. doi: 10.2214/AJR.12.9668.

16.

Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.

Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Hatabu H, Jänne PA, Johnson BE.

J Thorac Oncol. 2013 Aug;8(8):1059-68. doi: 10.1097/JTO.0b013e318294c909.

17.

Creating computable algorithms for symptom management in an outpatient thoracic oncology setting.

Cooley ME, Lobach DF, Johns E, Halpenny B, Saunders TA, Del Fiol G, Rabin MS, Calarese P, Berenbaum IL, Zaner K, Finn K, Berry DL, Abrahm JL.

J Pain Symptom Manage. 2013 Dec;46(6):911-924.e1. doi: 10.1016/j.jpainsymman.2013.01.016. Epub 2013 May 13.

18.

Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors.

Nishino M, Cardarella S, Dahlberg SE, Jackman DM, Ramaiya NH, Hatabu H, Rabin MS, Jänne PA, Johnson BE.

Lung Cancer. 2013 Mar;79(3):283-8. doi: 10.1016/j.lungcan.2012.11.007. Epub 2012 Dec 14.

19.

First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions.

Zornosa C, Vandergrift JL, Kalemkerian GP, Ettinger DS, Rabin MS, Reid M, Otterson GA, Koczywas M, D'Amico TA, Niland JC, Mamet R, Pisters KM.

J Natl Compr Canc Netw. 2012 Jul 1;10(7):847-56.

PMID:
22773800
20.

Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.

Nishino M, Cryer SK, Okajima Y, Sholl LM, Hatabu H, Rabin MS, Jackman DM, Johnson BE.

Cancer Imaging. 2012 Jun 29;12:225-35. doi: 10.1102/1470-7330.2012.0027.

21.

The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.

Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.

Clin Cancer Res. 2012 Aug 15;18(16):4406-14. doi: 10.1158/1078-0432.CCR-12-0357. Epub 2012 Jun 25.

22.

Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.

Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.

Clin Cancer Res. 2010 Dec 1;16(23):5873-82. doi: 10.1158/1078-0432.CCR-10-1588. Epub 2010 Oct 28.

23.

Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.

Sequist LV, Fidias PM, Temel JS, Kolevska T, Rabin MS, Boccia RV, Burris HA, Belt RJ, Huberman MS, Melnyk O, Mills GM, Englund CW, Caldwell DC, Keck JG, Meng L, Jones M, Brown GL, Edelman MJ, Lynch TJ.

J Thorac Oncol. 2009 Nov;4(11):1389-96. doi: 10.1097/JTO.0b013e3181b6b84b.

24.

Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.

Caglar HB, Baldini EH, Othus M, Rabin MS, Bueno R, Sugarbaker DJ, Mentzer SJ, Jänne PA, Johnson BE, Allen AM.

Cancer. 2009 Sep 15;115(18):4156-66. doi: 10.1002/cncr.24492.

25.

Pneumonectomy after chemoradiation: the Dana-Farber Cancer Institute/Brigham and Women's Hospital experience.

Allen AM, Mentzer SJ, Yeap BY, Soto R, Baldini EH, Rabin MS, Sugarbaker DJ, Bueno R.

Cancer. 2008 Mar 1;112(5):1106-13. doi: 10.1002/cncr.23283.

26.

Unresectable adenoid cystic carcinoma of the trachea treated with chemoradiation.

Allen AM, Rabin MS, Reilly JJ, Mentzer SJ.

J Clin Oncol. 2007 Dec 1;25(34):5521-3. No abstract available.

PMID:
18048830
27.

Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.

Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jänne PA.

J Clin Oncol. 2007 Mar 1;25(7):760-6. Epub 2007 Jan 16.

PMID:
17228019
28.

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA.

Clin Cancer Res. 2006 Jul 1;12(13):3908-14.

29.

Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer.

Johnson BE, Rabin MS.

Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):5022s-5026s. Review.

30.

The measurement of proton stopping power using proton-cone-beam computed tomography.

Zygmanski P, Gall KP, Rabin MS, Rosenthal SJ.

Phys Med Biol. 2000 Feb;45(2):511-28.

PMID:
10701518
31.

Characterization of human endotoxin lipopolysaccharide receptor CD14 expression in transgenic mice.

Hetherington CJ, Kingsley PD, Crocicchio F, Zhang P, Rabin MS, Palis J, Zhang DE.

J Immunol. 1999 Jan 1;162(1):503-9.

32.

Mantle irradiation alone for selected patients with laparotomy-staged IA to IIA Hodgkin's disease: preliminary results of a prospective trial.

Mauch PM, Canellos GP, Shulman LN, Silver B, Tarbell NJ, Come S, Rabin MS, Coleman CN.

J Clin Oncol. 1995 Apr;13(4):947-52.

PMID:
7707123
33.

Observation of Coulomb effects in production of pi + pi -, p pi -, and K+K- pairs in pp collisions at 27.5 GeV/c.

Wiencke LR, Church MD, Gottschalk EE, Hylton RA, Knapp BC, Sippach W, Stern BJ, Hartouni EP, Jensen DA, Klima B, Kreisler MN, Rabin MS, Strait JB, Uribe J, Christian DC, Gutierrez G, Holmes SD, Wehmann A, Avilez C, Forbush M, Huson FR, White JT.

Phys Rev D Part Fields. 1992 Nov 1;46(9):3708-3711. No abstract available.

PMID:
10015323
34.

Selective targeting of gene products with the megakaryocyte platelet factor 4 promoter.

Ravid K, Beeler DL, Rabin MS, Ruley HE, Rosenberg RD.

Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1521-5.

36.

Gastric emphysema due to carcinoma.

Philips RL, Rabin MS.

Australas Radiol. 1981 Mar;25(1):19-20. No abstract available.

PMID:
7271618
37.

Ultrasound demonstration of valvulae conniventes in small-bowel obstruction. A case report.

Rabin MS, Funston MR.

S Afr Med J. 1981 Jan 31;59(5):142-3.

PMID:
7455846
38.

The reflux gastroesophageal polyp.

Rabin MS, Bremner CG, Botha JR.

Am J Gastroenterol. 1980 May;73(5):451-2.

PMID:
7416145
39.

Ultrasound and barium study in the evaluation of upper abdominal masses.

Rabin MS, Funston MR, Kam J, Goudie E, Richter I, Schmaman I, Butterworth A.

S Afr Med J. 1980 Feb 16;57(7):231-5.

PMID:
7404135
40.
41.

The 'riding' ulcer: A report of 3 cases.

Richter IA, Rabin MS.

S Afr Med J. 1979 Oct 6;56(15):612-4.

PMID:
550413
42.
43.

High frequency of mutation to tubercidin resistance in CHO cells.

Rabin MS, Gottesman MM.

Somatic Cell Genet. 1979 Sep;5(5):571-83.

PMID:
294700
44.

Choledochocele. A case report.

Rabin MS, Price HI, Wellsted M.

S Afr Med J. 1979 Mar 17;55(11):429-30.

PMID:
432749
45.

Metastatic breast carcinoma presenting as obstructive jaundice. A report of 3 cases.

Rabin MS, Richter IA.

S Afr Med J. 1979 Mar 10;55(10):388-90.

PMID:
432736
46.

Radiological changes of reflux oesophagitis.

Rabin MS, Schmaman IB.

Clin Radiol. 1979 Mar;30(2):187-91.

PMID:
436368
47.

Polypoid leukemic infiltration of the large bowel.

Rabin MS, Bledin AG, Lewis D.

AJR Am J Roentgenol. 1978 Oct;131(4):723-4. No abstract available.

PMID:
102172
48.

Caecal bascule--a potential clinical and radiological pitfall. Case reports.

Rabin MS, Richter IA.

S Afr Med J. 1978 Aug 5;54(6):242-4.

PMID:
715600
49.

Correlation of the site of obstruction with the lesion by fine-needle percutaneous cholangiography.

Rabin MS, Bledin AG, Price HI.

S Afr Med J. 1978 Jul 1;54(1):15-7.

PMID:
694689
50.

Pneumatosis coli secondary to colonic obstruction. A case report.

Rabin MS, Bledin AG, Price HI.

S Afr Med J. 1978 Jun 24;53(26):1078-9.

PMID:
694685

Supplemental Content

Loading ...
Support Center